Cancer
Screenings
LucenceINSIGHT is an advanced multi-cancer screening test designed to detect multiple cancers early. Recommended for individuals aged 40 and above, or those with elevated personal and family risk factors, it allows you to look beyond standard health checks by choosing a screening plan tailored specifically to your lifestyle and medical background.
99% Specificity*
81% Sensitivity*
88% Accuracy*
100% Positive Predictive Value
All of 3 positive cancer signals correlated with newly diagnosed cancer patients in a prospective real-world cohort of 264 asymptomatic individuals in 2023.
in Tumor Localization
*The ctDNA-based LucenceINSIGHT demonstrated a specificity of 99.0% (310/313 self-declared healthy donors) and an overall sensitivity of 80.9% (233/288 cancer patients). Across the 21 tissue-of-origin classes analyzed, a high confidence prediction could be made in 62.4% (mean 73.6%, range 26.7%-100%) of cases with an overall accuracy of 87.7% (mean 84.9%, range 33.3%-100%). Reported from a retrospective cohort of 601 patient samples in 2024.
References: [6] Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042. [7] Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626.
LucenceINSIGHT® Packages
All packages includes Review of Results.
ctRNA tumor marker boost is included with LucenceINSIGHT® 50 and available as an optional add-on for LucenceINSIGHT® 12.
LucenceINSIGHT® Me
9 Cancers Types
6 Core Cancers
Breast cancer
Colorectal cancer
Liver cancer
Lung cancer
Pancreatic cancer
Thyroid cancer
+
3 Add-On Choices from the Panel
Nasopharyngeal Cancer
Esophageal Cancer
Stomach Cancer
Lymphoma (diffuse large B-cell lymphoma)
Kidney Cancer (clear cell)
Ovarian Cancer
Endometrial Cancer
Skin Cancer (Melanoma)
Cervical Cancer
Bladder Cancer
Prostate Cancer
$298
(Before GST)
LucenceINSIGHT® 12
12 Cancer Types
8 Foundation Cancers
Nasopharyngeal Cancer (EBV+)
Thyroid Cancer
Lung Cancer
Liver Cancer
Stomach Cancer
Pancreatic Cancer
Gastrointestinal Stromal Tumor (GIST)
Colorectal Cancer
+
Female
Breast Cancer
Ovarian
Cervical Cancer
Endometrial Cancer
Male
Esophageal Cancer
Kidney Cancer (clear cell)
Bladder Cancer
Prostate Cancer
$398
(Before GST)
LucenceINSIGHT® 50
50 Cancer Types
Eye cancer (Conjunctival; Uveal melanoma)
Thyroid cancer
Breast cancer
Lung cancer
Lung neuroendocrine tumor
Skin cancer (Melanoma; Non-melanoma)
Head & Neck:
Nasopharyngeal cancer (EBV+)
Oropharyngeal cancer (HPV+; HPV-)
Laryngeal cancer
Salivary gland cancer
Musculoskeletal:
Bone cancer
Soft tissue (Angiosarcoma; Smooth muscle sarcoma)
Myeloid:
Acute myeloid leukemia (Myelodysplasia-related; NPM1-mutated; Other defined genetic alterations)
Myeloproliferative neoplasms
Mast cell tumor
Myeloma
Lymphoid:
Non-Hodgkin lymphoma (Burkitt's; Diffuse large B-cell; Lymphoplasmacytic)
Hairy cell leukemia
Digestive:
Esophageal cancer
Liver cancer
Stomach cancer
Stomach neuroendocrine tumors
Pancreatic cancer
Biliary tract cancer (Intrahepatic, Extrahepatic, Gallbladder)
Gastrointestinal stromal tumor
Small intestine cancer
Colorectal cancer
Colorectal neuroendocrine tumors
Gynecologic:
Cervical cancer
Endometrial cancer
Ovarian cancer
Ovarian germ cell & stromal tumor
Vulvar cancer
Genitourinary:
Adrenal gland cancer
Kidney cancer (Clear cell)
Adult Wilms tumor
Bladder cancer
Penile cancer
Prostate cancer
Testis cancer
$600
(Before GST)
Fasting is not required. Please avoid heavy meals for 4 hours prior to your blood sample collection.
For patients undergoing dialysis, blood collection is recommended prior to your session.
LucenceINSIGHT is a cancer screening test designed to detect cancer signals. This test is not intended for use as a diagnostic tool and does not replace standard-of-care screening or the direct care of a healthcare provider.
Screening Add-Ons
1. ctRNA Tumor Marker Boost
Circulating tumor RNA (ctRNA) consists of cancer signals shed into the bloodstream by active cancer cells. Combining ctRNA with circulating tumor DNA (ctDNA) provides enhanced detection sensitivity over DNA markers alone.
12.5% Relative Increase in Sensitivity
for detecting lung, colon, and breast cancers when combining ctRNA with ctDNA*
Who Should Consider:
Family history of lung, colon, or breast cancer
Heavy smokers
*Sensitivity increase calculated as relative improvement over a ctDNA-only approach, based on an initial training dataset of three cancer types (breast, lung, colon) and independently validated on an internal dataset. Magnitude of increase varies by cancer type (data on file).
References: [8] Stejskal P, et al. Mol Cancer 2023; 22(15).
2. CardioHemeRISK™ Assessment
CardioHemeRISK™ evaluates subtle genetic alterations in blood cells (known as clonal hematopoiesis) to identify silent, elevated risks of cardiovascular events and hematologic conditions. By analyzing these genetic changes, the test generates a personalized risk score to guide preventative clinical care.
Healthy individuals aged 40 to 80
Cancer survivors previously treated with chemotherapy or radiation
Asymptomatic individuals with additional risk factors for atherosclerotic disease such as family history, hypertension, hyperlipidemia
Individuals with a history of atherosclerotic disease such as coronary artery disease (CAD) or ischemic stroke